ICU Medical (NASDAQ:ICUI) Director Elisha Finney Sells 1,285 Shares

ICU Medical, Inc. (NASDAQ:ICUI) Director Elisha Finney sold 1,285 shares of the firm’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total value of $180,439.70. Following the transaction, the director directly owned 3,995 shares of the company’s stock, valued at $560,977.90. This represents a 24.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

ICU Medical Stock Down 0.5%

Shares of ICUI traded down $0.74 during mid-day trading on Wednesday, reaching $142.48. The company had a trading volume of 60,505 shares, compared to its average volume of 269,822. The firm has a 50-day moving average price of $124.68 and a 200 day moving average price of $128.24. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44. The company has a market capitalization of $3.52 billion, a price-to-earnings ratio of -93.44 and a beta of 0.83. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $196.26.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. The business had revenue of $533.30 million during the quarter, compared to analyst estimates of $511.46 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. ICU Medical’s revenue was down 8.9% compared to the same quarter last year. During the same period last year, the business earned $1.59 EPS. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. On average, sell-side analysts forecast that ICU Medical, Inc. will post 4.11 EPS for the current year.

Institutional Investors Weigh In On ICU Medical

Institutional investors have recently modified their holdings of the stock. Cullen Frost Bankers Inc. bought a new position in ICU Medical in the second quarter worth about $38,000. SJS Investment Consulting Inc. boosted its stake in ICU Medical by 41,000.0% in the third quarter. SJS Investment Consulting Inc. now owns 411 shares of the medical instruments supplier’s stock valued at $49,000 after acquiring an additional 410 shares in the last quarter. Covestor Ltd grew its holdings in ICU Medical by 70.7% in the third quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 236 shares during the last quarter. Blue Trust Inc. increased its position in shares of ICU Medical by 17.6% during the second quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock worth $124,000 after purchasing an additional 141 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of ICU Medical by 11.6% during the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock valued at $128,000 after purchasing an additional 101 shares during the last quarter. 96.10% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ICUI has been the topic of a number of research analyst reports. Raymond James Financial lowered their price target on ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a report on Friday, August 8th. KeyCorp boosted their price objective on shares of ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. Piper Sandler boosted their target price on shares of ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Friday, September 5th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $181.75.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.